{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:40:02Z","timestamp":1785796802658,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung cancer is a major cause of cancer-related deaths. Alectinib is the first line of treatment for patients with ALK-positive lung cancer, but the survival rate beyond 2\u20133\u00a0years is low. Co-targeting secondary oncogenic drivers such as SHP2 is a potential strategy for improving drug efficacy. This is because SHP2 is expressed ubiquitously, but ALK expression is largely restricted to cancer cells. Thus, the combination of ALK and SHP2 inhibitors may provide a way to restrict synergistic cytotoxicity to cancer cells only, by reducing the dose of SHP2 inhibitors required for anticancer action and minimising SHP2-dependent systemic toxicity. The objective of this study was to investigate whether the combination of a SHP2 inhibitor (SHP099) with alectinib would synergistically suppress the growth of ALK-positive lung cancer cells. Our results demonstrated that the drug combination significantly and synergistically decreased cell viability at relatively low concentrations in ALK-positive H3122 and H2228 cells, due to G1 cell cycle arrest and increased apoptosis because of suppressed downstream RAS\/MAPK signalling. The drug combination also induced the expression of mediators of the intrinsic apoptotic pathway, Bim and cleaved caspase-3, and modulated the expression of cell cycle mediators cyclin D1, cyclin B1, and phosphorylated CDK1.<\/jats:p>","DOI":"10.1038\/s41598-023-37006-2","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T18:01:57Z","timestamp":1687284117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors"],"prefix":"10.1038","volume":"13","author":[{"given":"M. A.","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"37006_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fonc.2014.00204","volume":"4","author":"GJ Korpanty","year":"2014","unstructured":"Korpanty, G. J. et al. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front. Oncol. 4, 204 (2014).","journal-title":"Front. Oncol."},{"issue":"2","key":"37006_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1568009622666220107152014","volume":"22","author":"AR Bland","year":"2022","unstructured":"Bland, A. R. et al. Experimental determination of cancer drug targets with independent mechanisms of resistance. Curr. Cancer Drug Targets 22(2), 97\u2013107 (2022).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"11","key":"37006_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow, J. & Bivona, T. G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 17(11), 637\u2013658 (2017).","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"37006_CR4","first-page":"2669","volume":"120","author":"RS Mali","year":"2012","unstructured":"Mali, R. S. et al. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood J Am Soc Hematol 120(13), 2669\u20132678 (2012).","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"37006_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","volume":"26","author":"TA Ahmed","year":"2019","unstructured":"Ahmed, T. A. et al. SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors. Cell Rep. 26(1), 65-78 e5 (2019).","journal-title":"Cell Rep."},{"issue":"5","key":"37006_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13402-022-00698-1","volume":"45","author":"MD Asmamaw","year":"2022","unstructured":"Asmamaw, M. D. et al. A comprehensive review of SHP2 and its role in cancer. Cell. Oncol. 45(5), 729\u2013753 (2022).","journal-title":"Cell. Oncol."},{"issue":"7610","key":"37006_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"Y-NP Chen","year":"2016","unstructured":"Chen, Y.-N.P. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535(7610), 148\u2013152 (2016).","journal-title":"Nature"},{"issue":"2","key":"37006_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2016.07.010","volume":"30","author":"H Ran","year":"2016","unstructured":"Ran, H. et al. Sticking it to cancer with molecular glue for SHP2. Cancer Cell 30(2), 194\u2013196 (2016).","journal-title":"Cancer Cell"},{"issue":"10","key":"37006_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","volume":"58","author":"M Tajan","year":"2015","unstructured":"Tajan, M. et al. SHP2 sails from physiology to pathology. Eur. J. Med. Genet. 58(10), 509\u2013525 (2015).","journal-title":"Eur. J. Med. Genet."},{"issue":"8","key":"37006_CR10","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1073\/pnas.1215501110","volume":"110","author":"Z-Q Shi","year":"2013","unstructured":"Shi, Z.-Q. et al. S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke. Proc. Natl. Acad. Sci. 110(8), 3137\u20133142 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"37006_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fphar.2014.00118","volume":"5","author":"JC Dawson","year":"2014","unstructured":"Dawson, J. C. & Carragher, N. O. Quantitative phenotypic and pathway profiling guides rational drug combination strategies. Front. Pharmacol. 5, 118 (2014).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"37006_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","volume":"27","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signalling combinations with SHP2 inhibitor to block RTK signaling. Clin. Cancer Res. 27(1), 342\u2013354 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"37006_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2174\/1568009621666210729100647","volume":"21","author":"S Nensi","year":"2021","unstructured":"Nensi, S. & Ashton, J. ALK-positive non-small cell lung cancer; potential combination drug treatments. Curr. Cancer Drug Targets 21(9), 737\u2013748 (2021).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7153","key":"37006_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda, M. et al. Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561\u2013566 (2007).","journal-title":"Nature"},{"issue":"2","key":"37006_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin, J. J., Riely, G. J. & Shaw, A. T. Targeting ALK: Precision medicine takes on drug resistance. Cancer Discov. 7(2), 137\u2013155 (2017).","journal-title":"Cancer Discov."},{"issue":"1","key":"37006_CR16","doi-asserted-by":"publisher","first-page":"a001115","DOI":"10.1101\/mcs.a001115","volume":"3","author":"VR Holla","year":"2017","unstructured":"Holla, V. R. et al. ALK: A tyrosine kinase target for cancer therapy. Mol. Case Stud. 3(1), a001115 (2017).","journal-title":"Mol. Case Stud."},{"issue":"2","key":"37006_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/2278-330X.110506","volume":"2","author":"A Sahu","year":"2013","unstructured":"Sahu, A. et al. Crizotinib: A comprehensive review. South Asian J. Cancer 2(2), 91\u201397 (2013).","journal-title":"South Asian J. Cancer"},{"issue":"11","key":"37006_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","volume":"12","author":"AT Shaw","year":"2011","unstructured":"Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12(11), 1004\u20131012 (2011).","journal-title":"Lancet Oncol."},{"issue":"9","key":"37006_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm.3667","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M. et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 20(9), 1027\u20131034 (2014).","journal-title":"Nat. Med."},{"issue":"18","key":"37006_CR20","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","volume":"71","author":"T Sasaki","year":"2011","unstructured":"Sasaki, T. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Can. Res. 71(18), 6051\u20136060 (2011).","journal-title":"Can. Res."},{"issue":"1","key":"37006_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1508887","volume":"374","author":"AT Shaw","year":"2016","unstructured":"Shaw, A. T. et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374(1), 54\u201361 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"37006_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/cancers9090118","volume":"9","author":"SR Sabir","year":"2017","unstructured":"Sabir, S. R. et al. EML4-ALK variants: Biological and molecular properties, and the implications for patients. Cancers 9(9), 118 (2017).","journal-title":"Cancers"},{"key":"37006_CR23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan, P. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. JNCI J. Natl. Cancer Inst. 82, 1107\u20131112 (1990).","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"37006_CR24","doi-asserted-by":"publisher","first-page":"13955","DOI":"10.1038\/s41598-017-14289-w","volume":"7","author":"C Wilson","year":"2017","unstructured":"Wilson, C. et al. ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. Sci. Rep. 7(1), 13955 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"37006_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55376-4","volume":"9","author":"N Shrestha","year":"2019","unstructured":"Shrestha, N. et al. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. Sci. Rep. 9(1), 1\u201312 (2019).","journal-title":"Sci. Rep."},{"key":"37006_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114345","volume":"183","author":"A Bland","year":"2021","unstructured":"Bland, A. et al. The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochem. Pharmacol. 183, 114345 (2021).","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"37006_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","volume":"21","author":"M Goldoni","year":"2007","unstructured":"Goldoni, M. & Johansson, C. A mathematical approach to study combined effects of toxicants in vitro: Evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol. In Vitro 21(5), 759\u2013769 (2007).","journal-title":"Toxicol. In Vitro"},{"key":"37006_CR28","doi-asserted-by":"publisher","first-page":"172749","DOI":"10.1016\/j.ejphar.2019.172749","volume":"865","author":"AR Bland","year":"2019","unstructured":"Bland, A. R. et al. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. Eur. J. Pharmacol. 865, 172749 (2019).","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"37006_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/BJ20090387","volume":"420","author":"RH Palmer","year":"2009","unstructured":"Palmer, R. H. et al. Anaplastic lymphoma kinase: Signalling in development and disease. Biochem. J. 420(3), 345\u2013361 (2009).","journal-title":"Biochem. J."},{"key":"37006_CR30","doi-asserted-by":"crossref","unstructured":"Richards, M.W., et al., Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. 2015.","DOI":"10.1042\/BJ20150039"},{"issue":"10","key":"37006_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1080\/15384101.2015.1026514","volume":"14","author":"D Chen","year":"2015","unstructured":"Chen, D. et al. EML4 promotes the loading of NUDC to the spindle for mitotic progression. Cell Cycle 14(10), 1529\u20131539 (2015).","journal-title":"Cell Cycle"},{"issue":"4","key":"37006_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.4497","volume":"24","author":"L Dardaei","year":"2018","unstructured":"Dardaei, L. et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat. Med. 24(4), 512\u2013517 (2018).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37006-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37006-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37006-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T18:03:19Z","timestamp":1687284199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37006-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37006"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37006-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10041"}}